NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Location
Gooimeer 2 35, Narrden, Netherlands
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
NewAmsterdam Pharma Co B.V. (to 11/22/2022)
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 882 %
Debt-to-equity 15.7 %
Return On Equity -49.9 % +1.81%
Return On Assets -43.2 %
Operating Margin -387 % +70.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 110M shares +22.1%
Common Stock, Shares, Outstanding 108M shares +31%
Entity Public Float 1.05B USD +82.1%
Common Stock, Value, Issued 13.4M USD +32.2%
Weighted Average Number of Shares Outstanding, Basic 94.4M shares +14.8%
Weighted Average Number of Shares Outstanding, Diluted 94.4M shares +14.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 45.6M USD +223%
Research and Development Expense 151M USD -5.03%
Operating Income (Loss) -176M USD +3.65%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -242M USD -36.6%
Income Tax Expense (Benefit) -1K USD
Net Income (Loss) Attributable to Parent -242M USD -36.5%
Earnings Per Share, Basic -2.56 USD/shares -19.1%
Earnings Per Share, Diluted -2.56 USD/shares -19.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 772M USD +127%
Marketable Securities, Current 62.4M USD
Assets, Current 863M USD +149%
Property, Plant and Equipment, Net 242K USD +426%
Operating Lease, Right-of-Use Asset 431K USD +684%
Assets 865M USD +149%
Accounts Payable, Current 4.74M USD -72%
Liabilities, Current 107M USD +114%
Operating Lease, Liability, Noncurrent 202K USD
Liabilities 107M USD +82.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.47M USD +1.02%
Retained Earnings (Accumulated Deficit) -559M USD -76.2%
Stockholders' Equity Attributable to Parent 758M USD +163%
Liabilities and Equity 865M USD +149%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.6M USD -71.4%
Net Cash Provided by (Used in) Financing Activities 198M USD +8185%
Net Cash Provided by (Used in) Investing Activities -385K USD -5400%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 108M shares +31%
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares 0%
Deferred Tax Assets, Valuation Allowance 185M USD +42.2%
Deferred Tax Assets, Gross 185M USD +42.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -242M USD -36.5%
Operating Lease, Liability, Current 246K USD +310%
Deferred Tax Assets, Operating Loss Carryforwards 134M USD +76.5%
Unrecognized Tax Benefits 0 USD
Depreciation, Depletion and Amortization 15K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 105K USD +775%
Share-based Payment Arrangement, Expense 33.6M USD +36.8%